BRIEF-SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN

Reuters
23 May
BRIEF-SpringWorks <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN

May 23 (Reuters) - SpringWorks Therapeutics Inc SWTX.O:

  • SPRINGWORKS THERAPEUTICS RECEIVES POSITIVE CHMP OPINION FOR MIRDAMETINIB FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN

  • SPRINGWORKS THERAPEUTICS INC - EUROPEAN COMMISSION DECISION ON MIRDAMETINIB EXPECTED Q3 2025

Source text: ID:nGNX5Wfwsp

Further company coverage: SWTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10